GeneDx Holdings Corp. (NASDAQ: WGS) Financial Performance and Market Position

Core Insights - GeneDx Holdings Corp. operates in the genetic testing services sector, crucial for diagnosing and managing health conditions [1] - The company has shown strong financial performance, with recent earnings and revenue exceeding expectations [2][3][4] Financial Performance - GeneDx reported quarterly earnings of $0.14 per share, surpassing the Zacks Consensus Estimate of $0.11, resulting in a 27.27% earnings surprise [3] - The company achieved revenues of $121 million for Q4 2025, exceeding the Zacks Consensus Estimate by 1.5% and showing a significant increase from $95.64 million in the same quarter the previous year [4] - GeneDx has consistently surpassed consensus revenue estimates over the past four quarters, indicating robust financial health [4] Stock Performance - The current stock price of GeneDx (WGS) is $87.08, reflecting a 6.12% increase, with a market capitalization of approximately $2.52 billion [5] - The stock has experienced volatility, with a high of $170.87 and a low of $55.17 over the past year [5] Analyst Insights - Jefferies adjusted its price target for WGS to $150 from $180, indicating a potential upside of approximately 72.26% from the current trading price [2][6]